Buzz on the Bullboards: The 100-day checkup
What the 'Buzz'
Our Bullboards have up to 2 million pageviews a day. Get the inside scoop on conversations around the most significant trends and stock appreciations in our weekly wrap up.
Get 'Buzz on the Bullboards' delivered to your inbox every Thursday! Buzz on the Bullboards | Sign Up Here
Carney has pledged a firm stance against Washington's import tariffs and emphasized that Canada would need to invest billions to reduce its dependence on the U.S. This comes at a crucial time as data revealed that the Canadian economy contracted throughout Q1 2025, coinciding with U.S. President Donald Trump's first 100 days of his second term in office.
Trump Media and Technology Group Corp. (NASDAQ:DJT, Forum) has been making headlines for its poor performance, with its stock plummeting 28.04 per cent since the beginning of the year. This week, the company published a letter to shareholders, not explaining its poor performance, but rather defending its products and criticizing the 'legacy media's customary blizzard of fake news, undisguised propaganda, and manufactured hysteria about both our company and President Trump.' The letter also talked about how Trump warned that Americans can expect to find store shelves empty sooner than later. Just kidding, it obviously didn't.
The U.S. imposed, then delayed, a 10 per cent tariff on Canadian energy imports in February 2025, targeting crude oil and natural gas. Despite these challenges, Canadian energy stock Whitecap Resources Inc. (TSX:WCP, Forum) reported strong operating and unaudited financial results for the three months ended March 31, 2025. Whitecap's production averaged 179,051 boe/d, including 115,932 bbl/d of total liquids and 378,715 mcf/d of natural gas. This production was over 6,000 boe/d higher than their internal forecast due to strong production from new wells and better-than-expected base production.
Key highlights from Whitecap's first quarter include: Production growth : Production increased by 6 per cent compared to Q1 2024, with stronger-than-expected volumes from both unconventional and conventional assets.
: Production increased by 6 per cent compared to Q1 2024, with stronger-than-expected volumes from both unconventional and conventional assets. Funds flow : First quarter funds flow of $446 million ($0.75 per share) was 17% higher on a per share basis than Q1 2024 and 7% higher than Q4 2024. Free funds flow totaled $48 million after capital investments of $398 million.
: First quarter funds flow of $446 million ($0.75 per share) was 17% higher on a per share basis than Q1 2024 and 7% higher than Q4 2024. Free funds flow totaled $48 million after capital investments of $398 million. Return of capital : $107 million ($0.1824 per share) was returned to shareholders in base dividends, with an annual base dividend of $0.73 per share.
: $107 million ($0.1824 per share) was returned to shareholders in base dividends, with an annual base dividend of $0.73 per share. Balance sheet: Net debt of $987 million at the end of Q1 equates to a net debt to annualized funds flow ratio of 0.6 times, with significant available liquidity on their credit facility.
Another industry in focus is healthcare, which PM Carney pledged to protect in the face of the Trump Administration, saying we have relied on health cards, not credit cards, for our healthcare.
Theralase Technologies (TSXV:TLT, Forum), a healthcare stock focused on treating select cancers, bacteria, and viruses, recently discovered that its lead drug candidate, Ruvidar, has the potential to inhibit deubiquitinating enzymes (DUBs), which are linked to certain cancers and neurodegenerative diseases.
Ruvidar has been shown to induce oxidative stress in cancer cells through the production of Reactive Oxygen Species, facilitating their destruction without affecting healthy cells. The drug, alone and/or in combination with Transferrin to produce the compound Rutherrin, has delivered promising results against bladder cancer, lung cancer, and various viruses, including recent breakthroughs in the treatment of herpes.
According to this week's news release, DUBs cause cellular damage by removing ubiquitin or ubiquitin-like molecules from target proteins, which play an essential role in regulating gene expression, DNA repair, cytokine signaling, cell metabolism, cell cycle, and cell death. Theralase's study aims to build upon recent evidence that the alteration of DUBs is a key cause behind cancer drug resistance.
Keep an eye on this stock and you can find out more on the latest episode of Stockhouse's newest podcast, 'The Five-Minute Investor', which will feature more on Theralase on the next episode. Stay tuned!
After reading this, investors ought to deepen their due diligence into these news-making stocks to ensure their portfolios are up to date. The political and economic landscape is rapidly evolving, and staying informed about key developments can provide valuable insights for making strategic investment decisions.
For previous editions of Buzz on the Bullboards, click here.
Join the discussion: Find out what everybody's saying about these stock on Stockhouse's stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top image via Global News on Twitter / X.)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
an hour ago
- CBC
Chinese tariffs on Canadian canola have farmers bracing for the worst
A new Chinese tariff of over 75 per cent on Canadian canola seed takes effect today, effectively closing Canada's biggest export market for the product. The tariffs are an escalation in a mounting trade dispute between the two countries.
CBC
2 hours ago
- CBC
Manitoba business halting U.S. shipments over end to tariff exemption
A Manitoba small business owner says she's suspending shipments to the U.S. after a move by President Donald Trump that will make selling products to American customers more expensive. The "de minimis" exemption has allowed parcels with a value of $800 US or less to be shipped to that country without facing tariffs. But last month, Trump signed an executive order to eliminate the duty-free exemption for all countries starting Aug. 29. Leiah Bauer, owner of Apothecandy Shop, said she's decided she will stop taking orders from U.S. customers ahead of that. The local business, which sells handmade natural soaps and other beauty products, said in a social media post Wednesday carrying on with the shipments could become prohibitively expensive. "It hurts us in the long run, but we're small business owners and we pivot, and that's what we do," Bauer said. The Manitoba Craft Council says many of its members are scrambling to figure out how to respond to the change. "People are pretty upset," said Tammy Sutherland, the council's executive director. For some craftspeople in Manitoba, the U.S. market accounts for 40 to 60 per cent of sales, she said. "People are really struggling to find information about what the implications will be, what the needed paperwork is." Removal of tariff exemption causes trouble for some Manitoba entrepreneurs 3 hours ago Under what's called the 'de minimis' duty-free treatment, goods under $800 were exempt from U.S. tariffs. However, U.S. President Donald Trump has signed an executive order to remove the exemption, causing a lot of confusion and uncertainty for small businesses in Manitoba. The Canadian Federation of Independent Business said the exemption was a lifeline to small businesses. A survey conducted by the organization earlier this year suggested nearly a third of exporters used the de minimis rule to ship their goods. "It'll affect businesses all across Canada. Manitoba businesses will get hit hard," said Tyler Slobogian, senior policy analyst for the Prairies with the federation. "Many will have to ultimately scale back," he said. "They're looking at their options right now — different markets they can expand to and whatnot — but it's going to … result in added costs for them and significant reduction in their client base in the U.S." Slobogian said under the existing framework, businesses had to file less paperwork. Eliminating the exemption will result in an additional administrative burden for them, he said. The confusion is the hardest part, said Apothecandy's Bauer. "When you're a small business owner, you wear all the hats, and you're usually very busy wearing all those hats. Then all of a sudden, you need to start understanding international tariffs and trade agreements," she said. "[It] seems to be changing every single day."
Cision Canada
3 hours ago
- Cision Canada
Light AI reports Financial Results for Three and Six Months ended June 30, 2025
VANCOUVER, BC, /CNW/ - Light AI Inc. (" Light AI" or the " Company") (CBOE: CA) (CBOE: ALGO) (FSE: 0HC) (OTCQB: OHCFF), a healthcare technology company focused on developing artificial intelligence ("AI") health diagnostic and wellness solutions, today announced its financial and operating results for its second quarter of 2025 representing the three and six months ended June 30, 2025. Financial information is reported in Canadian dollars ("$") unless otherwise stated and in accordance with International Financial Reporting Standards ("IFRS"). Financial and Operating Results Summary for the three and six months ended June 30, 2025 The Company is currently in the development stage of its software technology offering anticipated to be completed with related commercialization commencing in late 2025. During the three months ended June 30, 2025, the Company had total operating expenses, exclusive of interest, depreciation and share based payments, of $4.0 million compared to $4.2 million for the three months ended March 31, 2025 and $2.0 million for the three months ended June 30, 2025. The change is primarily attributable to the Company's incremental investment in its product development with total research and development expenses of $1.4 million in Q2 2025 compared to $1.2 million for the three months ended March 31, 2025 and $1.1 million in the prior year period in addition to marketing and investor relations activities of approximately $2.1 million in Q2 2025 compared to $2.4 million for the three months ended March 31, 2025 and $0.3 million in the prior year period. The Company had total operating expenses of $8.3 million for the six months ended June 30, 2025 which increased from $3.8 million in the prior year period due primarily to marketing and investor relations expenses in addition to increased product development costs. The Company had cash of $9.4 million with total assets of $10.8 million as at June 30, 2025 compared to cash of $15.2 million with total assets of $17.1 million as at December 31, 2024. On January 8, 2025, the Company closed the second of two tranches of the Offering by issuing 2,757,000 units of the Company at $0.55 per unit for aggregate gross proceeds of $1,516,350. The Company had Adjusted Working Capital of $8.9 million as at June 30, 2025 compared to $14.6 million as at December 31, 2024. "Light AI continues to make progress towards commercializing its AI oriented wellness software application anticipated to be commercially available after Q3 2025," stated Peter Whitehead, CEO. "We are well positioned to capitalize on our sizable market opportunity leveraging Light AI's first mover advantage with our patented intellectual property and technology." Financial Statements and Management Discussion & Analysis Please see the Company's consolidated financial statements ("Financial Statements") and related Management's Discussion & Analysis ("MD&A") for more details. The Financial Statements for the three and six months ended June 30, 2025, and related MD&A have been reviewed and approved by the Company's Audit Committee and Board of Directors. For a more detailed explanation and analysis, please refer to the MD&A that has been filed on SEDAR+ at and is also available on the Company's website at Non-IFRS and Other Financial Measures This press release refers to the following non-IFRS measures: "Adjusted Working Capital" is comprised as current assets less current liabilities. Management believes Adjusted Working Capital is a useful indicator for investors, and is used by management, for evaluating the operating liquidity to the Company. See "Adjusted Working Capital Reconciliation" for a quantitative reconciliation of Adjusted Working Capital to the most directly comparable financial measure. Such non-IFRS measures and non-IFRS ratio do not have a standardized meaning under IFRS and may not be comparable to a similar measure disclosed by other issuers. About Light AI Inc. (CBOE CA: ALGO / FSE: 0HC / OTCQB: OHCFF) Light AI Inc. is a technology company focused on developing artificial intelligence health screening and diagnostic solutions. Light AI is developing a technology platform which represents the next generation of patient management: it applies AI algorithms to smartphone images—starting with images of Strep A and anticipated expansion with COVID19 along with other medical conditions —to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind—its hardware platform is the 4.5 billion smartphones that exist in the world today. Light AI is at the forefront of developing innovative screening and diagnostic solutions aimed at improving healthcare delivery worldwide. Their cutting-edge AI powered technology offers rapid, accurate, and cost-effective screening and diagnostic tools designed to address critical healthcare challenges. In pre-FDA validation studies, Light AI's algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A Streptococcus (GAS). The algorithm achieved a 96.57% accuracy rate and attained a Negative Predictive Value of 100%, indicating its high reliability in confirming the absence of Streptococcus A infection. Viral and GAS pharyngitis affects over 600 million people annually worldwide. If left untreated, GAS pharyngitis can lead to serious complications such as Rheumatic Heart Disease (RHD), which imposes a global economic burden exceeding $1 trillion annually. Light AI's technology offers a significant advancement in the accurate and timely identification of GAS pharyngitis, potentially reducing the incidence of RHD and its associated costs. Light AI's approach to applying AI to smartphone images can be expanded to other throat conditions, as well as other areas of analysis, such as the human eye and skin. Light AI's vision is to combine the smartphone with AI in-the-Cloud to create a Digital Clinical Lab that provides quick and accessible diagnosis for countless conditions that today require expensive and time-consuming imaging or lab processes. Light AI's commercial launch of its consumer-facing Wellness App initial offering is anticipated to be available in North America in Q3 2025. ON BEHALF OF THE COMPANY "George Reznik" George Reznik Chief Financial Officer Telephone: 604-307-6800 Email: [email protected] For more information, please contact the Company at [email protected] or visit Forward-Looking Information: This news release includes information, statements, beliefs and opinions which are forward-looking, and which reflect current estimates, expectations and projections about future events, including, but not limited to, the Company's research and development and commercialization initiatives, the anticipated inflection of the business, the Company's financial and operational performance and outlook and other statements that contain words such as "believe," "expect," "project," "should," "seek," "anticipate," "will," "intend," "positioned," "risk," "plan," "may," "estimate" or, in each case, their negative and words of similar meaning. By its nature, forward-looking information involves a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking information. These risks, uncertainties and assumptions could adversely affect the outcome of the plans and events described herein. Readers should not place undue reliance on forward-looking information, which is based on the information available as of the date of this news release. For a list of the factors that may affect any of the Company's forward-looking statements, please refer to the Company's annual information form dated April 14, 2025 and other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed under its SEDAR+ profile at
